ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 25173
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 25173

A Global Phase 2/3 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Extensive - Stage Small Cell Lung Cancer - C6461004

 

Disease Types: Lung Cancer Research

Eligibility Requirements:

Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
Participants have not received systemic therapy (chemotherapy, radiotherapy, chemoradiation) for ES-SCLC.
Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
Have at least one measurable lesion as the targeted lesion based on RECIST V1.1.
Eastern Cooperative Oncology Group performance status of 0 or 1.
Adequate organ function

For more information on this trial CLICK HERE .

Available at:

Virginia Oncology Associates